PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Revenue shows signs of recovery, but a disclaimer of opinion on the FY2025 audit triggered a delisting cause and trading suspension, making the outcome of the listing eligibility review the key variable.
2025 consolidated revenue rose about 52% year over year to KRW14.5 billion from KRW9.5 billion, yet the operating loss widened to KRW7.83 billion.
The operating loss narrowed for two consecutive quarters, moving from -KRW2.46 billion in 4Q25 to -KRW1.94 billion in 1Q26 and -KRW1.14 billion in 2Q26.
The FY2025 audit report received a disclaimer of opinion due to a scope limitation, triggering a delisting cause, and common shares have been suspended from trading since April 3, 2026.
Following completion of a third-party paid-in capital increase, the largest shareholder changed to Primecore Co., Ltd.
Media reports raised transparency concerns over a real-estate deal with BF Labs, itself a trading-halted company.
DHX Company is a KOSDAQ-listed distribution and consumer-goods firm operating IT device distribution, bicycle manufacturing, and bio businesses side by side. Its periodic filings describe the company as engaged in ICT distribution, bicycle manufacturing, and bio businesses.
In the ICT distribution segment, the company purchases and resells computer peripherals; it purchases and distributes IT components including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays, and also runs cosmetics import/distribution and food-and-beverage distribution.
In the bio segment, the company is described as engaging in a biomedical business offering a microbiome product for intractable skin diseases, REJURUB, and an AI-based digital brain diagnostic device.
More recently, it partnered with microbiome analytics firm EzGnome to pursue a joint pet-healthcare business as part of diversification.
The service analyzes a dog's gut microbiome to assess risk across eight major health categories, including digestive, kidney, and skin conditions, and delivers a health-management report. The company holds five unlisted consolidated subsidiaries.
Given the nature of the distribution business, component purchase costs are driven by global semiconductor and parts pricing, and the company competes against numerous small and mid-sized wholesalers in a structurally thin-margin market.
The bio/healthcare initiatives remain at an early stage, and neither their revenue contribution nor commercialization timeline has been disclosed in detail.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩3.7B | -₩1.9B | −51.4% |
| 2025Q3 | ₩4B | -₩1.5B | −37.3% |
| 2025Q4 | ₩3B | -₩2.5B | −81.1% |
| 2026Q1 | ₩3.2B | -₩1.9B | −60.8% |
| 2026Q2 | ₩3.4B | -₩1.1B | −33.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩8.3B | -₩6.5B | -₩14.5B | −77.6% | −24.3% | 38.5% |
| 2023 | ₩11.3B | -₩13.1B | -₩31.7B | −115.6% | −52.7% | 10.6% |
| 2024 | ₩9.5B | -₩6.1B | -₩17.6B | −64.1% | −36.5% | 18.9% |
| 2025 | ₩14.5B | -₩7.8B | -₩33.2B | −54.0% | −148.7% | 101.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 consolidated revenue rose about 52% year over year to KRW14.5 billion from KRW9.5 billion, but the operating loss widened to KRW7.83 billion, producing an operating margin of -54.0%.
Net loss attributable to owners reached KRW33.2 billion, more than double the revenue base, extending a fourth straight year of large losses following owner net losses of KRW14.5 billion, KRW31.7 billion, and KRW17.6 billion in 2022, 2023, and 2024 respectively.
Notably, the 4Q25 owner net loss of KRW22.5 billion far exceeded that quarter's operating loss of KRW2.5 billion, suggesting a sizable non-operating, likely one-off, item was recognized.
In 2026, however, the operating loss narrowed for two consecutive quarters to KRW1.9 billion in 1Q and KRW1.1 billion in 2Q, while revenue edged up from KRW3.2 billion to KRW3.4 billion over the same period.
Over the trailing four quarters (3Q25-2Q26), cumulative revenue was about KRW13.7 billion against an owner net loss of roughly KRW28.1 billion, indicating losses still substantially exceed revenue.
Operating cash flow was negative every year from 2022 through 2025, and the outflow widened to KRW8.9 billion in 2025 from KRW5.7 billion in 2024.
Owner equity fell by more than half in four years, from KRW59.6 billion in 2022 to KRW22.3 billion in 2025, while the debt ratio jumped from 18.9% in 2024 to 101.0% in 2025, marking a rapid deterioration in the balance sheet.
The ICT distribution business is exposed to global semiconductor cycles and currency swings, since prices of components such as graphics cards and DRAM move with these factors, directly affecting purchase costs and margins as AI server and PC demand fluctuates.
The domestic IT distribution market has numerous small and mid-sized wholesalers, resulting in intense competition, low entry barriers, and structurally thin profitability.
The bicycle manufacturing segment is a mature industry with limited growth and faces price competition from finished-bike makers and low-cost imports.
The microbiome-based healthcare and bio industry is drawing growing global interest, but commercialization as a drug requires lengthy clinical and approval processes, and related domestic regulations are still being established.
Non-medical microbiome diagnostic and management services, such as pet healthcare, carry a lighter regulatory burden and may monetize faster, though the market size remains unproven.
Meanwhile, the market-cap threshold for maintaining a KOSDAQ listing was raised from KRW15 billion to KRW20 billion effective July 1, 2026, and a KOSDAQ-listed company immediately triggers a delisting cause upon receiving an adverse, disclaimer, or qualified audit opinion, reflecting intensifying pressure to remove marginal companies.
Against this backdrop, DHX Company, having received a disclaimer of audit opinion, faces the same overriding priority as other small-cap distribution and bio peers: simply preserving its listing.
A delisting cause arose on April 3, 2026 following a disclaimer of audit opinion, and common share trading was suspended; subsequently, the KOSDAQ Market Division of the Korea Exchange announced on April 20, 2026 that it would grant the company an improvement period.
As a result, the suspension was extended to run until the delisting decision following the end of the improvement period, with the improvement period set to end 10 days after the statutory filing deadline of the next annual business report.
During this process, the largest shareholder changed to Primecore Co., Ltd. following completion of a third-party paid-in capital increase. In addition, on March 10, 2026 the company decided to issue KRW15 billion of new 34th-series unregistered, interest-bearing, unsecured private convertible bonds.
However, a related transaction — acquiring real estate in Anyang from BF Labs, itself under trading suspension, for a total of KRW14.5 billion — drew media scrutiny, with reports questioning whether DHX Company was effectively being used as a vehicle to facilitate BF Labs' property sale.
On the business side, the company is attempting to expand beyond its legacy ICT distribution channel, including launching a pet-healthcare service in partnership with microbiome analytics firm EzGnome.
Under the new controlling shareholder, the execution of a management normalization plan and progress on balance-sheet repair are likely to be the key variables in the upcoming improvement-period review.
It is worth first noting that this stock's recent history of trading suspension following a disclaimer of audit opinion makes it difficult to apply conventional market valuation metrics with confidence.
Because net losses have persisted for multiple years, calculating a price-to-earnings ratio is largely uninformative, and that is likely to remain the case until a clear earnings turnaround is confirmed.
On a price-to-book basis, the shares trade at a discount to recorded net asset value, a pattern that can be read as reflecting both the rapid erosion of equity from repeated losses and the overhang of delisting uncertainty.
On the dividend front, the company has not paid a cash dividend through its most recent fiscal year-end, so an income-based rationale does not apply.
Taken together, this stock's valuation appears to be driven less by financial ratios themselves and more by the outcome of the listing-eligibility review and the progress of its capital-structure overhaul.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
2025 revenue rose about 52% year over year to KRW14.5 billion, and the operating loss narrowed for two straight quarters in 2026, to KRW1.9 billion in 1Q and KRW1.1 billion in 2Q. Revenue also edged up from KRW3.2 billion in 1Q to KRW3.4 billion in 2Q, hinting the business may have passed a trough. Whether this improvement persists still needs confirmation over additional quarters.
Completion of a third-party paid-in capital increase brought in Primecore Co., Ltd. as the new controlling shareholder, and a KRW15 billion convertible bond issued to the same party added further operating capital.
This capital injection may partially ease equity-erosion risk and provide liquidity needed for management normalization during the improvement period. Whether the funds actually translate into business normalization will need to be verified through future disclosure of their use.
The pet-healthcare service developed with microbiome analytics firm EzGnome leverages the company's existing ICT distribution online-mall channel to graft on a new business line. Being a non-medical application, it carries a comparatively lighter regulatory burden that could allow faster commercialization. Its revenue contribution, however, has not yet been disclosed and remains to be confirmed.
The FY2025 audit report received a disclaimer of opinion due to a scope limitation, triggering a delisting cause, and common shares have been suspended from trading since April 3, 2026.
Although the exchange granted an improvement period, the final delisting decision will only be made afterward, leaving the outcome uncertain. It is also notable that, in past cases, only a small share of companies that received a disclaimer of opinion went on to secure a clean audit opinion in the following year.
Owner equity fell by more than half in four years, from KRW59.6 billion in 2022 to KRW22.3 billion in 2025, while the debt ratio surged from 18.9% in 2024 to 101.0% in 2025. Operating cash flow was negative every year from 2022 through 2025, indicating heavy reliance on external financing.
Potential conversion of outstanding convertible bonds could add further equity dilution, suggesting the erosion of the financial buffer may continue.
The company has repeated cycles of capital increases, convertible bond issuances, and controlling-shareholder changes over a short period. A property acquisition from BF Labs, itself under trading suspension, in Anyang drew media questions over financing delays and the nature of the counterparty.
Governance transparency under the new controlling shareholder and protections for minority shareholders remain areas that require further verification.
The disclaimer of audit opinion has triggered a delisting cause and suspended common share trading, with the final delisting decision to be made by the exchange after the improvement period ends.
If the exchange does not confirm implementation of a management-improvement plan and a corrected audit report within that period, delisting could follow.
If delisting is confirmed, a final trading (clean-up) process would ensue, and even absent that outcome, investors face an extended period without the ability to trade.
From 2022 through 2025, the company has recorded net losses far exceeding revenue and negative operating cash flow every year. The 2025 debt ratio surged to 101.0% from 18.9% a year earlier, and conversion of newly issued convertible bonds could result in further equity dilution. Reliance on external financing remains structurally high.
Amid repeated changes in the controlling shareholder and cycles of capital increases and convertible bond issuances, a real-estate acquisition from trading-halted BF Labs has drawn questions over financing delays and transaction intent.
Scrutiny of the new controlling shareholder Primecore's business purpose and financial capacity is also ongoing. Such opacity could lead to further market monitoring or disclosure corrections going forward.
Check whether the 3Q26 report is filed on time and whether any further accounting or audit-related issues are flagged.
This is when the KOSDAQ Market Committee is scheduled to conclude the improvement period and make a final delisting decision — the biggest fork in the road for whether trading resumes.
Watch for whether conversion requests begin on the convertible bonds issued to Primecore, any further changes in shareholding, and final completion of the Anyang property transaction.
Check whether new businesses such as pet microbiome healthcare begin contributing to revenue, and whether the recent improvement trend continues across the ICT distribution and bio segments.
DHX Company is a KOSDAQ-listed firm that has operated a mix of unrelated businesses spanning ICT distribution, bicycle manufacturing, and bio. 2025 revenue grew markedly from the prior year, yet both the operating loss and net loss remained well above the revenue base.
Some improvement has been observed in 2026, with the quarterly operating loss narrowing for two consecutive quarters, but a disclaimer of opinion on the FY2025 audit report triggered a delisting cause, suspending share trading since April 2026, with a final exchange decision still pending after the improvement period.
During this process, the controlling shareholder changed to Primecore and a large convertible bond was issued as part of an ongoing capital-structure overhaul, while a property acquisition from trading-halted BF Labs drew separate transparency concerns.
Owner equity has more than halved over four years and the debt ratio has surged, indicating a weaker financial buffer. On balance, the stock sits at the intersection of a positive revenue-recovery signal and structural risks tied to the delisting decision and governance opacity.
The outcome of the improvement-period review and the progress of management normalization under the new controlling shareholder are likely to be the key points to watch going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.